Dose-escalation study for the targeting of CD44v+ cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205)

Gastric Cancer

Volumn 20, Issue 2, 2017, Pages 341-349

  Shitara, Kohei ^a   Doi, Toshihiko ^a   Nagano, Osamu ^b   Imamura, Chiyo K ^b   Ozeki, Takeshi ^c   Ishii, Yuya ^b   Tsuchihashi, Kenji ^b   Takahashi, Shunji ^d   Nakajima, Takako E ^e   Hironaka, Shuichi ^f   Fukutani, Miki ^a   Hasegawa, Hiromi ^a   Nomura, Shogo ^a   Sato, Akihiro ^a   Einaga, Yasuaki ^b   Kuwata, Takeshi ^a   Saya, Hideyuki ^b   Ohtsu, Atsushi ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c Institute of Physical and Chemical Research   (Japan)

^d CANCER INSTITUTE HOSPITAL   (Japan)

^e ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f CHIBA CANCER CENTER   (Japan)

Author keywords

Cancer stem cell; CD44 variant positive; Gastric cancer; Sulfasalazine; xCT

Indexed keywords

CD44V ANTIGEN; GLUTATHIONE; SALAZOSULFAPYRIDINE; CD44 PROTEIN, HUMAN; HERMES ANTIGEN; NONSTEROID ANTIINFLAMMATORY AGENT; REACTIVE OXYGEN METABOLITE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTIGEN EXPRESSION; AREA UNDER THE CURVE; ARTICLE; BIOLOGICAL ACTIVITY; BLEEDING; BLOOD TOXICITY; CANCER CELL; CANCER STEM CELL; CELL POPULATION; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPONATREMIA; IN VITRO STUDY; IN VIVO STUDY; LEUKOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; OPEN STUDY; OXIDATIVE STRESS; STOMACH CANCER; THROMBOCYTOPENIA; TUMOR BIOPSY; TUMOR GROWTH; VOMITING; CANCER STAGING; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECTS; ENZYME IMMUNOASSAY; FOLLOW UP; LIVER NEOPLASMS; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; PATHOLOGY; PERITONEAL NEOPLASMS; PROGNOSIS; SECONDARY; STOMACH NEOPLASMS; TISSUE DISTRIBUTION; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIGENS, CD44; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASTIC STEM CELLS; PERITONEAL NEOPLASMS; PROGNOSIS; REACTIVE OXYGEN SPECIES; STOMACH NEOPLASMS; SULFASALAZINE; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84964047890     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-016-0610-8     Document Type: Article

References (20)

1. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med. 2011;17:313–9.
2. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov. 2009;8:579–91.
3. Nagano O, Okazaki S, Saya H. Redox regulation in stem-like cancer cells by CD44 variant isoforms. Oncogene. 2013;32:5191–8.
4. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. 2009;458:780–3.
5. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. 2003;4:33–45.
6. Nagano O, Saya H. Mechanism and biological significance of CD44 cleavage. Cancer Sci. 2004;95:930–5.
7. − and thereby promotes tumor growth. Cancer Cell. 2011;19:387–400.
8. Lau WM, Teng E, Chong HS, Lopez KA, Tay AY, Salto-Tellez M, et al. CD44v8–10 is a cancer-specific marker for gastric cancer stem cells. Cancer Res. 2014;74:2630–41.
9. Hirata K, Suzuki H, Imaeda H, Matsuzaki J, Tsugawa H, Nagano O, et al. CD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence. Br J Cancer. 2013;109:379–86.
10. Go SI, Ko GH, Lee WS, Kim RB, Lee JH, Jeong SH, et al. CD44 variant 9 serves as a poor prognostic marker in early gastric cancer, but not in advanced gastric cancer. Cancer Res Treat. 2015. doi:10.4143/crt.2014.227.
11. Yoshikawa M, Tsuchihashi K, Ishimoto T, Yae T, Motohara T, Sugihara E, et al. xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma. Cancer Res. 2013;73:1855–66.
12. Chen RS, Song YM, Zhou ZY, Tong T, Li Y, Fu M, et al. Disruption of xCT inhibits cancer cell metastasis via the caveolin-1/β-catenin pathway. Oncogene. 2009;28:599–609.
13. Zhang W, Trachootham D, Liu J, Chen G, Pelicano H, Garcia-Prieto C, et al. Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nat Cell Biol. 2012;14:276–86.
14. Yae T, Tsuchihashi K, Ishimoto T, Motohara T, Yoshikawa M, Yoshida G, et al. Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell. Nat Commun. 2012;3:883.
15. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2015;376:687–97.
16. Salazopyrin summary of product characteristics. http://emc.medicines.org.uk/emc/assets/c/html/DisplayDoc.asp?DocumentID=3344. Accessed 25 Feb 2014.
17. Yamasaki Y, Ieiri I, Kusuhara H, Sasaki T, Kimura M, et al. Pharmacogenetic characterization of SSZ disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans. Clin Pharmacol Ther. 2008;84:95–103.
18. Fierro S, Yoshikawa M, Nagano O, Yoshimi K, Saya H, Einaga Y. In vivo assessment of cancerous tumors using boron doped diamond microelectrode. Sci Rep. 2012;2:901.
19. Gu GZ, Xia HM, Pang ZQ, Liu ZY, Jiang XG, Chen J. Determination of sulphasalazine and its main metabolite sulphapyridine and 5-aminosalicylic acid in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2011;879:449–56.
20. − transporter using positron emission tomography in patients with non–small cell lung or breast cancer. Clin Cancer Res. 2012;18:5427–37.